Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lessened by Forte Capital LLC ADV

Forte Capital LLC ADV decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 79.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,689 shares of the company's stock after selling 33,589 shares during the quarter. Forte Capital LLC ADV's holdings in Novo Nordisk A/S were worth $603,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL boosted its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. purchased a new position in Novo Nordisk A/S in the first quarter valued at about $27,000. Park Square Financial Group LLC purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $29,000. Finally, Transce3nd LLC purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on NVO. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded down $0.97 during midday trading on Friday, hitting $64.32. 8,032,293 shares of the company's stock were exchanged, compared to its average volume of 7,363,987. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74. The firm has a market cap of $287.19 billion, a P/E ratio of 19.03, a PEG ratio of 1.26 and a beta of 0.64. The stock's 50 day moving average price is $70.37 and its 200-day moving average price is $74.53. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion for the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.